A placebo-controlled Phase 2b clinical trial combining imdusiran, interferon and NA therapy in Subjects With Chronic Hepatitis B Infection
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Imdusiran (Primary) ; Interferon; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Therapeutic Use
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to Arbutus Biopharma media release, company anticipates to initiate this trial in the first half of 2025.
- 13 Jan 2025 According to Arbutus Biopharma media release, company announced that Subject to regulatory approval, the clinical trial is anticipated to enroll approximately 170 HBeAg-negative cHBV patients with baseline HBsAg less than or equalto 1000 IU/mL.